Media headlines about Collegium Pharmaceutical (NASDAQ:COLL) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 45.2367014023891 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
COLL stock traded up $0.03 during midday trading on Tuesday, hitting $25.18. The company’s stock had a trading volume of 20,883 shares, compared to its average volume of 532,027. The company has a current ratio of 0.83, a quick ratio of 0.80 and a debt-to-equity ratio of 3.91. Collegium Pharmaceutical has a twelve month low of $9.01 and a twelve month high of $29.90. The firm has a market capitalization of $879.63 million, a P/E ratio of -10.30 and a beta of 0.73.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.02). The business had revenue of $63.70 million during the quarter, compared to analyst estimates of $51.92 million. Collegium Pharmaceutical had a negative net margin of 78.22% and a negative return on equity of 72.87%. The firm’s quarterly revenue was up 2835.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.79) earnings per share. equities research analysts forecast that Collegium Pharmaceutical will post -1.22 EPS for the current fiscal year.
Several equities research analysts have issued reports on COLL shares. ValuEngine upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 12th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research note on Monday, April 16th. Cantor Fitzgerald started coverage on shares of Collegium Pharmaceutical in a research note on Monday, June 11th. They issued a “buy” rating and a $40.00 price target on the stock. TheStreet lowered shares of Collegium Pharmaceutical from a “c-” rating to a “d” rating in a research note on Monday, May 7th. Finally, BidaskClub lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Wednesday, May 30th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Collegium Pharmaceutical currently has an average rating of “Buy” and an average price target of $32.14.
In other news, insider Paul Brannelly sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $27.92, for a total transaction of $279,200.00. Following the transaction, the insider now directly owns 128,336 shares in the company, valued at approximately $3,583,141.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alison B. Fleming sold 4,096 shares of the business’s stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $27.00, for a total transaction of $110,592.00. Following the transaction, the insider now owns 53,362 shares in the company, valued at $1,440,774. The disclosure for this sale can be found here. Insiders have sold a total of 288,179 shares of company stock worth $7,134,731 over the last 90 days. 13.87% of the stock is owned by company insiders.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.